Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome

Not Applicable

• Conditions: Demyelinating Autoimmune Diseases, CNS
• Interventions: Biological: blood sample

• Registration Number: NCT02862301
• Lead Sponsor: Centre Hospitalier Universitaire de Besancon

Brief Summary

The aim of the study is to compare the enzymatic activity of HATs and HDACs in peripheral blood mononuclear cell (PBMC) of patients with a clinically isolated syndrome (CIS group) and healthy controls (control group).

Detailed Description

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS). Clinically isolated syndrome (CIS) is often a sign of multiple sclerosis and the term refers to the first episode of neurologic symptoms experienced by a patient. Possible presentations of CIS include optic neuritis, a brain stem and/or cerebellar syndrome, a spinal cord syndrome, or occasionally cerebral hemispheric dysfunction. An accurate diagnosis at this time is important because people with a high risk of developing MS are encouraged to begin treatment in order to delay or prevent a second neurologic episode and, therefore, the onset of MS.

The innate and adaptative immune systems play an important role in pathophysiology of MS, acting in interaction with environmental, genetic, and epigenetic factors.

Epigenetic modifications, such as DNA methylation and histone modification, alter DNA accessibility and chromatin structure, thereby regulating patterns of gene expression. These processes are crucial to normal development and differentiation of distinct cell lineages in the adult organism. Histone acetylation, through the family of histone acetyl transferase (HAT), is most consistently associated with promoting transcription. Deacetylation of histones correlates with CpG methylation and the inactive state of chromatin. There are 4 classes of histone deacetylase enzymes (HDACs), with members capable of deacetylation of histones and/or other protein targets. Acetylation homeostasis is a key regulator of both immune cell activation. Of note, potent histone deacetylase inhibitors (HDACi) endowed with antiinflammatory and neuroprotective properties have been identified. Efficacy of HDACi in experimental models of MS has been reported consistently. This study could provide information on the mechanisms involved.

Study Timeline

• Study Start: 2016-04
• Study First Submitted: 2016-08-03
• Study First Submitted QC: 2016-08-08
• Study First Posted: 2016-08-11
• Status Verified: 2019-11
• Last Update Submitted: 2019-11-15
• Last Update Posted: 2019-11-18
• Primary Completion: 2020-06
• Study Completion: 2020-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

• Clinically isolated syndrome within the last 6 weeks (CIS group)
• Healthy volunteer, free of any inflammatory disease (control group)
• Patient able to understand the reason of the study
• Signed informed consent

Exclusion Criteria

• Pregnancy
• Systemic corticosteroid therapy (>1mg/kg)
• Immunosuppressive/immunomodulatory therapy (prior or ongoing) (CIS group)
• Patient with ongoing infection (Control group)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Control group	blood sample	Healthy volunteers, free of any inflammatory disease. A blood sample is performed on the day of inclusion.
CIS group	blood sample	patients with Clinically isolated syndrome. A blood sample is performed on the day of inclusion and after 3 months.

Primary Outcome Measures

Name	Time	Method
HDAC/ HAT enzymatic activity (ratio)	day of inclusion

Trial Locations

Locations (1)

University Hospital; 🇫🇷 Besançon, France